Risk of hematologic toxicities and peripheral neuropathy with nab-paclitaxel in treatment of malignancy: an up-to-date metaanalysis

Yihua Liu; Yihua Liu; Huiting Fan; Huiting Fan; Ying Zhang; Ying Zhang; Yong Yang; Yong Yang; Hongsheng Lin; Hongsheng Lin

doi:10.18632/oncotarget.23287

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/15/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Risk of hematologic toxicities and peripheral neuropathy with nab-paclitaxel in treatment of malignancy: an up-to-date metaanalysis

Yihua Liu, Yihua Liu, Huiting Fan, Huiting Fan, Ying Zhang, Ying Zhang, Yong Yang, Yong Yang, Hongsheng Lin _ and Hongsheng Lin _

Yihua Liu1,2, Huiting Fan1, Ying Zhang1, Yong Yang3 and Hongsheng Lin1

1 Department of Oncology, Guang’anmen Hospital, Affiliated to China Academy of Chinese Medical Sciences, Beijing, 100053, China

2 Beijing University of Chinese Medicine, Beijing, 100029, China

3 Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Beijing, 100010, China

Correspondence to:

Hongsheng Lin, email: [email protected]

Keywords: nab-paclitaxel; taxanes; peripheral neuropathy; hematological toxicities; meta-analysis

Received: August 19, 2017 Accepted: November 13, 2017 Epub: December 15, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23287

Publication Alerts

Withdrawal Notice

Research Papers:

Risk of hematologic toxicities and peripheral neuropathy with nab-paclitaxel in treatment of malignancy: an up-to-date metaanalysis